Paxman launches neuropathy system to help prevent chemotherapy nerve damage

Paxman has launched its first neuropathy-focused device in Europe, aiming to reduce the risk and severity of chemotherapy-induced peripheral neuropathy, or CIPN, a side effect that can disrupt daily life and cancer treatment. The rollout comes with new clinical data and marks the company’s expansion beyond scalp cooling.

Why it matters: - Chemotherapy-induced peripheral neuropathy can cause lasting numbness, pain, tingling and loss of sensation in the hands and feet. - CIPN can make everyday tasks harder, including walking, writing, dressing and sleeping. - Severe symptoms can force chemotherapy dose reductions, delays or discontinuation. - Paxman’s launch adds a new preventive option in a field with no established standard therapy.

What happened: - Paxman announced the commercial launch of the Paxman Neuropathy System, a cryocompression device designed to help reduce the risk and severity of CIPN. - The launch is Paxman’s first major product expansion beyond scalp cooling for chemotherapy-induced hair loss. - The company is rolling out the system in the UK, France, Germany, the Netherlands, Spain and Italy after recent regulatory approvals. - Pilot programs are already underway in the UK, with more European sites expected in the coming months.

The details: - Paxman said the new system uses cryocompression technology to target a major unmet need in cancer care. - Clinical data released alongside the launch came from a prospective multicentre Phase I/II study published in JCO Oncology Advances. - The study evaluated patients receiving taxane-based chemotherapy and found the device was safe, well tolerated and associated with low rates of CIPN. - Among 146 evaluable patients, no participants developed severe neuropathy. - Patient-reported clinically significant sensory symptoms stayed low throughout follow-up. - A separate review in Therapeutic Advances in Medical Oncology examined the causes, impact and potential prevention strategies for CIPN. - That review highlighted cryotherapy and cryocompression as among the most promising emerging interventions.

Between the lines: - Paxman is trying to extend its brand from scalp cooling leadership into broader side-effect management in oncology. - The 2025 acquisition of Dignitana strengthened Paxman’s position in scalp cooling before this product expansion. - The launch arrives as more evidence builds around cryocompression, but the field still lacks a widely accepted prevention standard for CIPN. - The company’s move also reflects demand for treatments that help patients stay on prescribed chemotherapy regimens.

What's next: - Further research is continuing through the randomized SWOG S2205 ICE COMPRESS study in the U.S. - Dana-Farber Cancer Institute is running an additional clinical trial evaluating the Paxman Neuropathy System. - Paxman expects additional center launches across Europe in the coming months.

The bottom line: - Paxman is betting that new clinical data and early European rollout can turn cryocompression into a practical tool against one of cancer care’s most persistent side effects.